Introduction
The purpose of the National Institute for Health and Clinical Excellence (NICE) is to give health professionals guidance on providing NHS patients with the highest attainable standards of clinical care (Rawlins, 1999) and to advise individuals and communities on how to improve health and prevent disease (Littlejohns and Kelly, 2005) . Clinicians are expected to take NICE guidance fully into account when making their individual clinical decisions and managers and health service commissioners are expected to incorporate NICE's recommendations into their business and strategic planning. NICE's appraisals are subject to a further directive from the Department of Health which requires local health communities to make the funding available within three months of publication of the guidance (Secretary of State, 2003) . All NICE guidance is incorporated into the national standards (including those related to public health) against which Trusts will be assessed by the Healthcare Commission (DoH, 2005a) and are being proposed as a key feature of the Quality Outcomes Framework which reimburses general practitioners for achieving quality clinical targets (National Institute for Health and Clinical Excellence and NHS Quality Improvement Scotland, 2005) . This means that NICE guidance is not only key to achieving excellence in clinical practice aimed at individuals, but also in determining health policy at local and national levels.
This responsibility requires NICE guidance to be based on the best available evidence; but deciding on what constitutes best evidence can be fraught with difficulties. Historically there have been paradigm wars between advocates of qualitative and quantitative evidence. Fortunately an uneasy truce exists but there is a continuing debate over issues such as internal and external validity, reliability, and 'fitness for purpose'. Furthermore, the fact that developing guidance based on the 'best available evidence' also requires value judgements (both scientific and social) to be made, is only now being acknowledged (Rawlins and Culyer, 2004) . In this paper we explore three aspects of utilising the evidence base in order to inform national healthcare policy: first, how NICE gets the best evidence; second, what it does when good evidence is not available; and third, how a more comprehensive evidence base can be generated in the future.
Getting the best evidence Choosing the evidence (or, the weaknesses of traditional hierarchies)
Since the birth of the 'evidence-based medicine' movement, there has been a general agreement that a systematic review is a necessary step in all evidence gathering and, indeed, so-called 'secondary research' is an essential pre-requisite for any new research endeavour. However, in the world of health policy, the saying 'forgetfulness being an essential component of originality' applies all too often. A rapid assessment of existing data sources would have prevented many futile innovations being inflicted on the NHS. The requirement to summarise evidence from diverse sources has meant that attention has been directed to assessing the quality of the data, and the concept of ranking evidence became popular. 'Hierarchies of evidence' originated in the late 1970s when the Canadian Task Force introduced a classification and applied it to grade its recommendations (Canadian Task Force on the Periodic Health Examination, 1979) . The notion that evidence should be assessed in a hierarchical fashion has been driven by a desire, above all else, to protect internal validity. This one-size-fits-all approach has inherent weaknesses that apply equally to decision-making in clinical practice, public health and health policy.
Conventional hierarchies focus on the effectiveness of therapeutic interventions with Randomised Controlled Trials (RCTs) as their 'gold standard'. RCTs, when properly conducted, are unquestionably powerful tools for assessing the effectiveness of therapeutic interventions. By minimising bias, they offer the most reliable study designs for ensuring internal validity. RCTs, however, are rarely adept at demonstrating external validity; and they struggle with questions about diagnostic accuracy or less common adverse effects of treatments. Moreover, they are sometimes unnecessary or impossible. No-one, for example, doubts the effectiveness of thyroxin in the treatment of myxoedema, or arthroplasty for osteoarthritis of the hip. Finally, it is more likely that studies with positive results will get published, resulting in an overly optimistic view of effectiveness. To counteract this, it is important that all relevant trials should be available for scrutiny (Gibson, 2004; Rennie, 2004; Whittington et al., 2004) .
Indiscriminate application of hierarchies can also have perverse consequences. Where the benefits of an intervention with modest, but unequivocal, health gain have been demonstrated in one or more RCTs, its use may assume disproportionate importance in relation to other measures that could achieve greater health gain. Alternatively, interventions that have not been examined by formal RCTs may be inappropriately ignored. This may be especially relevant when comparing the potential benefits to society of recently licensed drugs against off-patent drugs, where the incentive to carry out RCTs is much less.
Hierarchies tend to downgrade the validity, and relevance, of observational studies; some, indeed, ignore such designs altogether, making it hard for guidance authors to frame and address perfectly reasonable questions about risk factors, diagnosis or investigation. This approach is especially dangerous where it undervalues harms. Hierarchies also have the tendency to reduce the impact of cost-effectiveness considerations: economic evidence is rarely based solely on RCTs, and most cost-effectiveness analyses require additional data sources or assumptions (Wailoo et al., 2004) .
Finally, the use of hierarchies of evidence does not necessarily ensure consistency. Their objective nature may be illusory because there are significant judgmental components in all grading schemes. Some of these difficulties and inconsistencies when grades of recommendations are based on pre-ordained grades of evidence can be seen in Figure 1 . Collaborative re-analysis. Studies identified by This is a systematic review of cohort studies with development group by consultation with collaboration members only; no re-analysis of individual patient data and, thus, no systematic reviewers database searches performed. Systematic quality requirement for quality assessment of the included assessment of studies not undertaken; consistency studies. It covers 90% of worldwide checks only made: e ev vi id de en nc ce e l le ev ve el l I II II I epidemiological data, redefines outcome measures from • The Million Women 3 study: first principles with a detailed heterogeneity assessment. Cohort study: e ev vi id de en nc ce e l le ev ve el l I II II I Of the highest methodological quality (internal validity) and applicability to UK population.
• The Million Women study: Cohort study; this is an appropriate design to answer questions of harm/aetiology, particularly for rare side-effects of treatments. High internal validity with stratification and sensitivity analysis for potential confounders.
Comments on body of
• Evidence statement:
• The body of evidence consists of two high quality studies, evidence by systematic
The totality of the evidence suggests that HRT is applicable to the UK population and of appropriate reviewers with the input associated with an increase in breast cancer risk. design. The findings (relative risk) of both studies are of guidance developers T Th he e b bo od dy y o of f e ev vi id de en nc ce e i is s g gr ra ad de ed d a at t l le ev ve el l I II II I. . highly consistent.
• The body of the evidence suggests that HRT is associated with an increase in breast cancer risk. There is a g go oo od d e ev vi id de en nc ce e b ba as se e to support the above statement.
Clinical recommendations
• Women with a family history of breast cancer who • Women with a family history of breast cancer who are by guidance developers are considering taking, or already taking, HRT considering taking, or already taking, HRT should be with the advice of should be informed of the increase in breast cancer informed of the increase in breast cancer risk with type systematic reviewers risk with type and duration of HRT. ( (C C) ) and duration of HRT. K KE EY Y R RE EC CO OM MM ME EN ND DA AT TI IO ON N b ba as se ed d o on n • HRT usage in a woman at familial risk should be g go oo od d e ev vi id de en nc ce e restricted to as short a duration and as low a dose
• HRT usage in a woman at familial risk should be as possible. ( (D D) ) restricted to as short a duration and as low a dose as possible. K KE EY Y R RE EC CO OM MM ME EN ND DA AT TI IO ON N b ba as se ed d o on n g go oo od d e ev vi id de en nc ce e Figure 1 Assessing evidence: an example. This figure summarises the evidence assessment process undertaken by the NICE guideline developer based on a traditional hierarchy carrying a value judgement for each individual study (level of evidence). The third column presents a fit-forpurpose approach as described in further detail in Chalkidou et al., (under review) and demonstrates how the application of a rigid hierarchy could inappropriately downgrade the evidence base and the clinical recommendations it underpins.
Littlejohns and Chalkidou Evidence for health policy
The option of converting the existing hierarchies into more sophisticated instruments to address these concerns has been explored in a range of initiatives. In 1998 a comprehensive set of hierarchies were developed to address the full range of clinical questions which was used successfully in the development of a pneumonia guideline (British Thoracic Society Standards of Care Committee, 2001). The Oxford Centre for Evidence-Based Medicine (2005) has proposed a similar approach, where, for questions about prognosis or prevalence, for example, it is systematic reviews of cohort studies that occupy the highest level of evidence and not RCTs. The GRADE group (2004) is working on a system that accounts for factors additional to internal validity (such as generalisability and appropriateness of study design or the balance of risks and benefits) for grading the quality of evidence and strength of recommendations. The US Preventive Services Task Force also considers other factors when deciding on the strength of recommendations including disease burden and the characteristics of the intervention (Harris et al., 2001) . In both these latter approaches, however, RCTs continue to occupy a pre-eminent position.
So complex has this field become that Glasziou and colleagues claim that a crossroads has been reached (Glasziou et al., 2004) and conclude that there are two possible ways forward: either to extend, improve and standardise current evidence hierarchies; or to abandon them, and their associated levels of evidence, altogether. The authors declined to choose between these alternatives, but invited organisations such as NICE to review their approach.
The continued use of both traditional and more recent evidence hierarchies provides serious challenges to the Institute. It is time-consuming and frustrating to seek to engineer a solution for each occasion that the hierarchical approach is unsuitable or inappropriate. The expansion of the Institute's programmes into public health and the variety of evidence (including health economic models) that NICE must consider makes it difficult for the Institute to see how the pre-ordained hierarchy approach can be sustained (Chalkidou et al., under review) .
Assessing the quality of the evidence
Whether a hierarchy or 'fit for purpose' approach is adopted, individual studies still need to be assessed for their attempts to minimise bias. Many checklists are available which can be used to evaluate design but, in addition, broader issues such as the funding and commissioning of the studies need to be scrutinised as they can also affect the magnitude of effect (Fossati et al., 2002; Lexchin et al., 2003) .
In addition to assessing individual studies on the basis of their internal and external validity, the body of evidence underpinning a recommendation must also be appropriately assessed. In this paper we describe a decision analytic framework within which the totality of evidence can be assessed, an approach that has been adopted by NICE Appraisals Programme.
However, whatever the strength of the evidence, value judgements are required to translate the evidence into guidance. These can be both scientific and social judgements and more often than not a combination of the two. To inform scientific judgements, the Institute commissions its data gathering and analysis from external academic institutions, uses independent multidisciplinary advisory structures to formulate the guidance and has a formal consultation and appeal process. To support decisions related to social judgements, NICE has established a Citizen's Council (NICE Citizen's Council, 2005) and the NICE Board has recently approved a set of social values that all its advisory committees and guideline development groups are required to take into account when making their decisions (see Figure 2) .
Principle 1
The fundamental principles that underpin the processes by which NICE guidance is developed should be maintained for current, and applied to future, forms of guidance.
Principle 2
For both legal and bioethical reasons those undertaking technology appraisals and developing clinical guidelines must take account of economic considerations.
Principle 3 NICE guidance should not support the use of interventions 1 for which evidence of clinical effectiveness is either absent or two weak for reasonable conclusions to be reached.
Principle 4
In the economic evaluation of particular interventions, cost-utility analysis is necessary but should not be the sole basis for decisions on cost effectiveness.
Principle 5 NICE guidance should explain, explicitly, reasons for recommending -as cost effective -those interventions with an incremental costeffectiveness ratio in excess of £20,000 to £30,000 per QALY.
Principle 6 NICE clinical guidance should only recommend the use of a therapeutic or preventive intervention for a particular age group when there is clear evidence of differences in the clinical effectiveness of the measure in different age groups that cannot be identified by any other means.
Principle 7
In setting priorities there is no case for the Institute or its advisory bodies to distinguish between individuals on the basis of gender or sexual orientation unless these are indicators for the benefits or risks of preventative or therapeutic interventions.
Principle 8
In developing clinical guidance for the NHS, no priority should be given based on individuals' income, social class or position in life and individuals' social roles, at different ages, when considering cost effectiveness. Nevertheless, in developing its approach to public health guidance, NICE wishes its advisory bodies to promote preventative measures likely to reduce those health inequalities that are associated with socioeconomic status.
Principle 9 NICE clinical guidance should only recommended the use of an intervention for a particular racial (ethnic) group if there is clear evidence of differences between racial (ethnic) groups in the clinical effectiveness of the intervention that cannot be identified by any other means.
Principle 10
NICE and its advisory bodies should avoid denying care to patients with conditions that are, or may be, self-inflicted (in part or in whole). If, however, self-inflicted cause(s) of the condition influence the clinical or cost effectiveness of the use of an intervention, it may be appropriate to take this into account.
Principle 11
Although respect for autonomy, and individual choice, are important for the NHS and its users, they should not have the consequence of promoting the use of interventions that are not clinically and/or cost effective.
Principle 12
It is incumbent on the Institute and its advisory bodies to respond appropriately to the comments of stakeholders and consultees and, where necessary, to amend the guidance. The board is aware, however, that there may be occasions when attempts are made (directly or indirectly) to influence the decisions of its advisory bodies that are not in the broad public interest. The board urges the Institute, and members of its advisory bodies, to resist such pressures.
Principle 13
Priority for patients with conditions associated with social stigma should only be considered if the additional psychological burdens have not been adequately taken into account in the cost-utility analyses.
F Fi ig gu ur re e 2 2 Social value judgements. The principles below, approved by the NICE Board (September 2005, www.nice.org.uk/page.aspx?o=271978), describe the social value judgements that should, generally, be incorporated into the processes used to develop NICE guidance and be applied when preparing individual items of NICE guidance. The Institute recognises, however, that there will be circumstances when -for valid reasonsdepartures from these general principles are appropriate. When departures from these principles are made, the reasons should be explained.
What if there is no evidence (or, broadening the concept of evidence)?
In November 2004, the World Health Organisation ministerial summit reinforced the need for promoting evidence-based policy making: 'Health policy, public health, and service delivery should be based on reliable evidence derived from high quality research.' The summit called for action by 'national governments to establish sustainable programmes to support evidence-based public health and health care delivery systems, and evidence-based health policies' (World Health Organisation, 2004) . Despite acknowledging the importance of evidence as a basis for policy decisions, the reality of limited fit-for-purpose information around most interventions, and broader programmes NICE is invited to issue guidance on, makes implementation of such an approach a challenge. Since NICE was established, 68% of clinical recommendations from NICE guidelines were based on expert opinion or were 'Good Practice Points' (Cluzeau, pers. comm.) . Is it right to argue that in the cases above, NICE's recommendations were not evidence-based? Is the strength of evidence, determined by applying the conventional, often inappropriate hierarchies of evidence, the only factor suited to inform evidence-based policy decisions?
Traditional evidence, such as peer-reviewed published studies, is only one of the many types of potentially fit-for-purpose evidence to be considered within the broader framework of evidence-based decision-making. Adhering to a rigid approach of recommending a technology only on the basis of unambiguous evidence could result in an unacceptable delay in the adoption of new technologies, so decisions need to be made even in the absence of conclusive evidence. Evidence from all sources should be sought and used in a standardised way to inform these decisions: observational data and expert consensus opinion, economic evaluations and riskassessment models, information from audit and feasibility studies.
Decision analytic frameworks
Decision analysis (Claxton et al., 2002) attempts to incorporate, in a generic framework, not only conventional evidence such as the efficacy of the technology under consideration, but also additional factors relating to the intervention, such as the balance of harms and benefits, relevant costs and the opportunity cost accompanying a decision to recommend the technology. Furthermore, decision analysis allows consideration of the consequences accompanying a positive or negative decision about a technology before the decision is taken. And it is this opportunity to assess in advance the consequences of a decision that makes decision analysis attractive to decision-makers.
This approach is further detailed in the NICE Methods Guide to Technology Appraisals (NICE, 2004) . By adopting a decision analytic approach, NICE committees can now take account of all types of evidence ranging from patient experiences of services or drugs to sophisticated economic analyses, and from expert opinion obtained through elicitation or consensus methods to complex risk-assessment models. Each piece of evidence is weighted on the basis of its fitness-for-purpose to address the decision problem (i.e. question) under consideration rather than a rigid hierarchy.
In addition, uncertainty can be quantified and, thus, taken into consideration by the guidance developers.
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Value-of-information analysis (VOI)
Part of the analysis of uncertainty is to identify the key areas where uncertainty is most critical for the decision problem under consideration. This information can then inform NICE research priorities. Value-of-information is one method that can be used within the decision analytic framework to establish the value for money of additional research and where that research should be focused (Ginnelly et al., 2005) . In other words, the value-of-information analysis helps the decision-maker to decide on whether the uncertainty surrounding an area is large enough to warrant collection of data through further research.
However, the above quantitative method is not the only tool for identifying research priorities.
Gaining new evidence
In order to ensure that NICE guidance is evidence-based, each piece of NICE guidance highlights relevant evidence gaps and makes recommendations for further research. These recommendations are usually identified during a systematic review of the evidence base, but can also be recognised following a cost-effectiveness analysis and accompanying quantification of uncertainty using VOI (value-of-information analysis). In 2003 NICE established its own R&D programme to prioritise and support appropriate research projects and programmes. Guidance developers are supported in framing their research questions in order to make them acceptable to research commissioners. NICE then actively promotes the resulting research priorities to the appropriate external organisations. For example, the NHS R&D Service and Delivery Organisation programme is in the process of commissioning research projects in the field of falls prevention and multiple sclerosis, and the NHS R&D Technology Assessment programme is considering funding research in the field of childhood depression and pre-operative testing.
Although rarely practised, NICE guidance developers can issue a recommendation that a technology is only used within the context of an appropriate clinical study. This occurs when there is significant uncertainty about the clinical or cost-effectiveness of the technology in question (VOI can help decide on the value-for-money of research). It is often more cost-effective in these circumstances for a technology to be used in the controlled setting of a research study that will inform the evidence base and allow the right decision to be made in future guidance updates. Reversing support for an intervention following further research that demonstrates the intervention is not cost-effective is always difficult. Furthermore, issuing a positive recommendation amidst great uncertainty that could be resolved by further research carries the dual risks of wasting resources and compromising any possibility of research in this area.
The NHS provides a unique opportunity for this type of research to be undertaken efficiently and is one of the aims of the new NHS R&D Strategy (DoH, 2005b) . But achieving this in an increasing devolved health service with 'contestability' at its core is going to require careful attention to incentives whilst ensuring that research is seen as a means of reducing uncertainty for patients and practitioners and an essential component of any quality assessment and performance management framework.
